摘要
目的通过体外培养人离体子宫内膜增生症(EH)腺上皮细胞,比较凋膜止崩方靶向干预用药前后细胞中Rb2/p130的表达影响,揭示凋膜止崩方靶向祛除增生子宫内膜的机制。方法对30例子宫内膜增生症患者的子宫内膜组织进行分离、提取腺上皮细胞,应用细胞免疫荧光法对腺上皮细胞进行鉴定;采用实时定量聚合酶链反应(Realtime PCR)分别检测用药组与空白组细胞中Rb2/p130的表达变化。结果 Rb2/p130基因在用药组(大、中、小剂量)中表达量依次递减,差异有显著性(P<0.05),空白对照组细胞中Rb2/p130的表达低于用药各组。结论 Rb2/p130基因的表达在用药组(大、中、小剂量)中表达逐渐降低,提示Rb2/p130可能参与了子宫内膜癌前病变的病理过程,用药剂量与Rb2/p130的表达之间的关系对指导临床治疗有一定意义。
Objective Through isolated human endometrial hyperplasia （EH） cultured in vitro and glandular epithelial cells, compared to Tiaomo Zhibeng fluid square target influence to the expression of Rb2/pl30 in the ceils before and after the treatment, explore the mechanism of intervention, Tiaomo Zhibeng fuild targeted dispel endometrial hyperplasia. Methods separated 30 patients with endometrial hyperplasia endometrium glandular epithelium cell extraction, identification of glandular epithelial cells were subjected to use cell immunofluorescence ; quantitative real - time polymerase chain reaction （Realtime PCR） were detected the expression change of Rb2/pl30 medicine group and blank group in cells. Results Rb2/pl30 gene in the medication group （high, middle, low dose） the expression level of decreasing, the difference was significant （ P 〈 0.05 ）, the expression of Rb2/pl30 cells in blank control group is lower than the medication groups. Conclusion the expression of Rb2/p130 gene in the drug group （high, middle, low dose） decreased gradually, suggested that Rb2/pl30 may be involved in the pathological process of endometfial precancerous lesions, the relationship between the expression of Rb2/pl30 and dosages has certain significance for guiding the clinical treatment.
出处
《陕西中医学院学报》
2014年第6期73-76,共4页
Journal of Shaanxi College of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(81173290)
